edoc-vmtest

Items where Author is "Asselah, T."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: Yes
Number of items: 2.

Yes

Zeuzem, S. and Asselah, T. and Angus, P. and Zarski, J. P. and Larrey, D. and Mullhaupt, B. and Gane, E. and Schuchmann, M. and Lohse, A. W. and Pol, S. and Bronowicki, J. P. and Roberts, S. and Arasteh, K. and Zoulim, F. and Heim, M. and Stern, J. O. and Nehmiz, G. and Kukolj, G. and Bocher, W. O. and Mensa, F. J.. (2013) Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1 : SOUND-C1 final results. Antiviral therapy, Vol. 18, H. 8. pp. 1015-1019.

Zeuzem, S. and Asselah, T. and Angus, P. and Zarski, J. P. and Larrey, D. and Mullhaupt, B. and Gane, E. and Schuchmann, M. and Lohse, A. and Pol, S. and Bronowicki, J. P. and Roberts, S. and Arasteh, K. and Zoulim, F. and Heim, M. and Stern, J. O. and Kukolj, G. and Nehmiz, G. and Haefner, C. and Boecher, W. O.. (2011) Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology, Vol. 141, H. 6. pp. 2047-2055.

This list was generated on Sat Nov 23 04:29:03 2024 CET.